Nirsevimab

International data show that greater than 90% nirsevimab uptake in newborns corresponds to greater than 70% reduction in RSV-associated infant hospitalisations. Direct neonatal immunoprophylaxis with nirsevimab has a structural advantage over maternal vaccination because it can protect infants born before the RSV season begins. A German study found nirsevimab targeting infants aged 1–5 months reduced infection rates by an additional 18% compared to targeting those older than 6 months. Nirsevimab coverage reached 90% in the pilot health region, with 690 of 766 eligible newborns receiving the prophylaxis. Spain achieved over 90% nirsevimab coverage as one of the first EU countries to administer it broadly, confirming large-scale feasibility. Ireland's Pathfinder Programme provided intramuscular nirsevimab to all newborns born between 1 September 2024 and 28 February 2025.